RTW Biotech Opportunities Ltd (LSE: RTWG), a London-listed investment fund focused on biopharmaceutical and medical technology assets, has announced the repurchase of 235,000 ordinary shares at a price of $2.39 per share on 9 November 2026. The repurchased shares will be held in treasury and will carry no voting rights. The buyback was conducted through broker Jefferies International Limited under shareholder authority granted at the company's Annual General Meeting in June 2026, and investors may be watching the programme closely as a potential signal of management's confidence in the fund's net asset value.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) is a closed-ended investment fund managed by RTW Investments, LP
  • The company repurchased 235,000 ordinary shares at $2.39 per share on 9 November 2026, to be held in treasury
  • Total treasury shares now stand at 27,147,093, with voting rights in the company reduced to 318,820,347
  • Investors should watch whether further buybacks are conducted ahead of the next AGM authority expected in 2027

235,000 Ordinary Shares Repurchased at $2.39 and Transferred to Treasury

The announcement states that RTW Biotech Opportunities Ltd completed the buyback of 235,000 ordinary shares on 9 November 2026 at a price of $2.39 per ordinary share. Following settlement, the company's total issued ordinary share capital stands at 345,967,440 shares. Of these, 27,147,093 are now held in treasury and attract no voting rights. The total number of shares with active voting rights is therefore 318,820,347, a figure the company notes may be used by shareholders as the denominator for interest-notification calculations under the FCA's Disclosure and Transparency Rules.

June 2026 AGM Authority Permits Repurchase of Up to 14.99% of Ordinary Shares

The buyback programme operates under authority granted by shareholders at RTW Biotech Opportunities Ltd's Annual General Meeting held in June 2026. That authority permits the company to repurchase a maximum of 14.99% of its ordinary shares. The announcement confirms the authority remains in force until either the next shareholder authority — expected to be granted at the 2027 AGM — or until it is expressly revoked. The company has instructed Jefferies International Limited as its broker for buyback transactions, in accordance with FCA Listing Rules and its general repurchase authority.

Net Asset Value Cap and Treasury Intentions Govern RTW's Buyback Pricing Policy

The announcement clarifies that no maximum aggregate consideration has been determined for the buyback programme. However, the company has stated it is unable to pay a price for any ordinary shares that would equate to a premium to the fund's net asset value. It remains the company's current intention to hold all repurchased shares in treasury rather than cancel them. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a healthcare-focused investment firm with expertise spanning biopharmaceutical and medical technology sectors, investing in companies developing next-generation therapies and technologies.